News and Announcements

Keep up with the latest headlines

Recent News

Stay connected, stay ahead. Know everything that matters, as it happens. From the very latest industry news, reports, papers, and studies. Would you like to see your news here? Email the admin and we will get it linked.

Cellular Mass Response to Therapy Correlates With Clinical Response for a Range of Malignancies
January 23, 2024

Cellular Mass Response to Therapy Correlates With Clinical Response for a Range of Malignancies

Cancer patients with advanced-stage disease have poor prognosis, typically having limited options for efficacious treatment, and genomics-based therapy guidance continues to benefit only a fraction of patients. Next-generation ex vivo approaches, such as cell mass-based response testing (MRT), offer an alternative precision medicine approach for a broader population of patients with cancer, but validation of clinical feasibility and potential impact remain necessary.

Read MORE
Cancer Patient Lab Meeting #11 - "Functional Precision Testing"
January 15, 2024

Cancer Patient Lab Meeting #11 - "Functional Precision Testing"

Tony Letai, MD, PhD, Professor at Dana Farber Cancer Institute, and President, Society for Functional Precision Medicine, led a discussion on "Functional Precision Medicine for Advanced Cancer". As we look at novel, personalized therapies, how can we have confidence that they will work?

Read MORE
Cancer Patient Lab Meeting #18 - "Functional Drug Testing and AI/ML for Treatment Decisions"
January 15, 2024

Cancer Patient Lab Meeting #18 - "Functional Drug Testing and AI/ML for Treatment Decisions"

Noah Berlow, PhD, CTO, First Ascent Biomedical, and Diana Azzam, PhD, Assistant Professor at Florida International University, led a discussion on their approach to functional drug testing and using AI/ML to guide complex treatment decisions for advanced cancer patients.

Read MORE
Cancer Patient Lab Meeting #13 - "Organoids Guide Treatment Decisions"
January 15, 2024

Cancer Patient Lab Meeting #13 - "Organoids Guide Treatment Decisions"

Payel Chatterjee, Chief Scientist, SEngine Precision Medicine, led a discussion on the role of organoids in guiding cancer treatment decisions. The value proposition of “functional testing” (applying 100 or more drugs to fresh tumor tissue and seeing how the cancer responds) is that this very direct approach can identify unexpected drugs to try, and extraordinary results, for some patients.

Read MORE
Ex vivo drug response profiling for response and outcome prediction in hematologic malignancies: the prospective non-interventional SMARTrial
October 16, 2023

Ex vivo drug response profiling for response and outcome prediction in hematologic malignancies: the prospective non-interventional SMARTrial

Ex vivo drug response profiling is a powerful tool to study genotype–drug response associations and is being explored as a tool set for precision medicine in cancer. Here we conducted a prospective non-interventional trial to investigate feasibility of ex vivo drug response profiling for treatment guidance in hematologic malignancies (SMARTrial, NCT03488641). We conclude that ex vivo drug response profiling is clinically feasible and has the potential to predict chemotherapy response in individuals with hematologic malignancies beyond clinically established genetic markers.

Read MORE
PMNET Meeting in Riga, Latvia
September 11, 2023

PMNET Meeting in Riga, Latvia

Many SFPM stalwarts will be speaking at the PMNET meeting in Riga, Latvia October 12-13. Please visit pmnetforum.com to register for in-person or virtual access to this exciting meeting!

Read MORE
Extraordinary clinical response to ibrutinib in low-grade ovarian cancer guided by organoid drug testing
July 24, 2023

Extraordinary clinical response to ibrutinib in low-grade ovarian cancer guided by organoid drug testing

Here we describe a case study of a patient with low grade serious ovarian cancer who underwent two rounds of chemotherapy and two surgeries. Despite this, her cancer progressed to the point that she was in rapid decline and entering hospice care.  Drug testing on tumor organoids derived from the second surgical resection showed exceptional sensitivity to the BTK inhibitor ibrutinib.  Although ibrutinib is not FDA approved for the treatment of ovarian cancer, the tumor board and oncologist recommended and requested its off-label use for this case.  Following daily ibrutinib as a mono therapy, the patient exhibited a dramatic and prolonged clinical response, resulting in stable disease for >24 months.

Read MORE
Cancer stem cell assay-guided chemotherapy improves survival of patients with recurrent glioblastoma in a randomized trial
June 6, 2023

Cancer stem cell assay-guided chemotherapy improves survival of patients with recurrent glioblastoma in a randomized trial

Therapy-resistant cancer stem cells (CSCs) contribute to the poor clinical outcomes of patients with recurrent glioblastoma (rGBM) who fail standard of care (SOC) therapy. ChemoID is a clinically validated assay for identifying CSC-targeted cytotoxic therapies in solid tumors.

Read MORE
Precision Medicine Networking Forum
May 26, 2023

Precision Medicine Networking Forum

Join us October 12 - 13, 2023 as 50+ speakers, 400+ participants, and 20+ countries come together for one goal; to improve patient care and outcomes by promoting the development and adoption of Precision Medicine!  Registration is open!

Read MORE
Treatment guidance by 3D patient-derived organoids met primary end-point in prospective interventional trial
May 16, 2023

Treatment guidance by 3D patient-derived organoids met primary end-point in prospective interventional trial

Drug sensitivity testing including a broad panel of standard and off-label drugs showed that 50% of the patients showed progression-free-survival after 2 months of 3D organoid guided treatment. The primary end-point was set to 40%. The trial was conducted at University Hospital of Southern Denmark, Vejle and published in Journal of Experimental & Clinical Cancer Research.

Read MORE